Alfred Forrester
Psychiatry · Timonium, MDNPI 1003814401
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.3% of the total across 440 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 29 manufacturers, the largest accounting for just 14.4% — the pattern of someone who eats at a lot of different presentations. Among psychiatry clinicians in MD with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 440 payments — averaging $26.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$2K
- Otsuka America Pharmaceutical, Inc.$1K
- Takeda Pharmaceuticals U.S.A., Inc.$871
- Lundbeck LLC$696
- Supernus Pharmaceuticals, Inc.$685
- plus $5K from 23 others
What the payments were for
- Food & beverage$11,25398%
- Education$1962%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 70 | $1,645 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 51 | $1,600 |
| Otsuka America Pharmaceutical, Inc. | 38 | $1,064 |
| Takeda Pharmaceuticals U.S.A., Inc. | 42 | $871 |
| Lundbeck LLC | 33 | $696 |
| Supernus Pharmaceuticals, Inc. | 35 | $685 |
| Neurocrine Biosciences, Inc. | 26 | $637 |
| Tris Pharma Inc | 19 | $527 |
| Johnson & Johnson | 13 | $435 |
| Axsome Therapeutics, Inc. | 13 | $415 |
| Corium, LLC | 11 | $412 |
| Jazz Pharmaceuticals Inc. | 10 | $406 |
| Ironshore Pharmaceuticals Inc. | 8 | $279 |
| Teva Pharmaceuticals USA, Inc. | 6 | $232 |
| Idorsia Pharmaceuticals US Inc | 4 | $188 |
| Almatica Pharma LLC | 7 | $180 |
| Sunovion Pharmaceuticals Inc. | 4 | $160 |
| Alkermes, Inc. | 8 | $157 |
| Neos Therapeutics, LP | 8 | $149 |
| Adlon Therapeutics L.p. | 8 | $131 |
| Indivior Inc. | 5 | $119 |
| Bausch Health US, LLC | 6 | $115 |
| Eisai Inc. | 4 | $77 |
| Sage Therapeutics, LLC | 1 | $71 |
| Vanda Pharmaceuticals Inc. | 3 | $56 |
| E.r. Squibb & Sons, L.L.C. | 2 | $44 |
| Shire North American Group Inc | 2 | $35 |
| Avanir Pharmaceuticals, Inc. | 2 | $34 |
| Alfasigma USA, Inc. | 1 | $28 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CAPLYTA$578
- VRAYLAR$475
- REXULTI$367
- SUNOSI$250
- QELBREE$250
- Quillivant$231
- Quillichew ER$231
- Dyanavel XR$231
- JORNAY PM$125
- Azstarys$125
- SPRAVATO$125
- QUVIVIQ$125
- Auvelity$109
How this compares
$11,449 in reported general payments places this provider in the 95th percentile of 851 psychiatry providers in Maryland.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 11 | $144,001 |
| RexultiBrexpiprazole | 22 | $30,599 |
| VraylarCariprazine Hcl | 14 | $29,965 |
| TrintellixVortioxetine Hydrobromide | 27 | $26,121 |
| AuvelityDextromethorphan Hbr/Bupropion | 11 | $11,738 |
| MydayisDextroamphetamine/Amphetamine | 20 | $6,937 |
| FocalinDexmethylphenidate Hcl | 12 | $4,803 |
| Methylphenidate Er (La)Methylphenidate Hcl | 21 | $4,427 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 50 | $4,228 |
| Aripiprazole | 26 | $2,960 |
| Asenapine Maleate | 13 | $2,391 |
| Vilazodone Hcl | 37 | $2,306 |
| Duloxetine Hcl | 47 | $2,281 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 84 | $1,963 |
| Bupropion XlBupropion Hcl | 32 | $1,868 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $637 | $144,00111 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $1,064 | $30,59922 claims |
| AbbVieVraylar | $1,645 | $29,96514 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $871 | $26,12127 claims |
| Axsome Therapeutics, Inc.Auvelity | $415 | $11,73811 claims |
| Shire North American Group IncMydayis | $35 | $6,93720 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 851 psychiatry providers in Maryland.
Other psychiatry in Timonium
- John VaethBaltimore$2.1M
- Scott AaronsonBaltimore$334K
- Jamal FawazHagerstown$321K
- Thomas LaughrenRockville$283K
- Adam RothAnnapolis$210K
- Robert LehmanBaltimore$140K
- Karen AndersonBaltimore$117K
- Orlando DavisBaltimore$104K
- Paul LeberPotomac$85K
- Akira SawaBaltimore$69K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.